(0.03%) 5 208.25 points
(0.05%) 39 018 points
(-0.13%) 18 171 points
(-0.32%) $78.23
(0.91%) $2.22
(-0.47%) $2 320.30
(-0.50%) $27.48
(0.75%) $972.15
(0.01%) $0.928
(0.32%) $10.86
(0.13%) $0.797
(-0.18%) $91.18
4.94% $ 1.000
Live Chart Being Loaded With Signals
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox...
Stats | |
---|---|
Dzisiejszy wolumen | 428 981 |
Średni wolumen | 434 558 |
Kapitalizacja rynkowa | 89.63M |
EPS | $0 ( 2024-05-02 ) |
Następna data zysków | ( $-0.220 ) 2024-06-20 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.060 |
ATR14 | $0.00400 (0.40%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-20 | Kozin Marc D | Buy | 100 000 | Stock Option (Right to Buy) |
2024-03-20 | Kozin Marc D | Buy | 0 | |
2024-02-14 | Andriole Michael T. | Sell | 1 744 | Common Stock |
2024-02-14 | Laspaluto Michelle | Sell | 1 940 | Common Stock |
2024-02-14 | Jakeman David | Sell | 2 660 | Common Stock |
INSIDER POWER |
---|
88.99 |
Last 99 transactions |
Buy: 5 160 750 | Sell: 1 392 397 |
Wolumen Korelacja
Chimerix Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
ALXO | 0.966 |
GXGX | 0.964 |
NAKD | 0.962 |
KNSA | 0.957 |
MICS | 0.956 |
CMLS | 0.956 |
BWB | 0.954 |
SIRI | 0.954 |
GOOD | 0.954 |
ORPH | 0.952 |
10 Najbardziej negatywne korelacje | |
---|---|
PTOC | -0.971 |
MCFT | -0.969 |
LGAC | -0.964 |
APXI | -0.963 |
NVSA | -0.962 |
AGGR | -0.961 |
GFGD | -0.961 |
FRSG | -0.959 |
FTPA | -0.959 |
ACQR | -0.959 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Chimerix Inc Korelacja - Waluta/Towar
Chimerix Inc Finanse
Annual | 2023 |
Przychody: | $324 000 |
Zysk brutto: | $323 000 (99.69 %) |
EPS: | $-0.930 |
FY | 2023 |
Przychody: | $324 000 |
Zysk brutto: | $323 000 (99.69 %) |
EPS: | $-0.930 |
FY | 2022 |
Przychody: | $33.82M |
Zysk brutto: | $33.38M (98.68 %) |
EPS: | $1.970 |
FY | 2021 |
Przychody: | $1.98M |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-2.01 |
Financial Reports:
No articles found.
Chimerix Inc
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej